SNSE · Sensei Biotherapeutics, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | - | - | - | - | - | - | - | - | - | - |
| SG&A | $19.71M | - | $2.31M | $2.67M | $3.55M | - | $3.19M | $3.20M | $3.81M | - |
| Total Operating Expenses | $170.63M | - | $4.85M | $5.21M | $7.27M | - | $7.82M | $7.79M | $8.73M | - |
| D&A | $29.0K | - | - | - | $30.0K | - | $140.0K | $135.0K | $137.0K | - |
| Operating Income | ($170.63M) | - | ($4.85M) | ($5.21M) | ($7.27M) | - | ($7.82M) | ($7.79M) | ($8.73M) | - |
| Interest Expense | - | - | $6.0K | $10.0K | $13.0K | - | $21.0K | $24.0K | $28.0K | - |
| Income Tax | $0 | - | - | - | $0 | - | - | - | $0 | - |
| Net Income | ($170.24M) | - | ($4.57M) | ($4.94M) | ($6.86M) | - | ($7.25M) | ($7.14M) | ($7.99M) | - |
| EPS - Basic | ($131.45) | - | ($3.62) | ($3.91) | ($5.40) | - | ($5.80) | ($5.60) | ($6.40) | - |
| EPS - Diluted | ($131.45) | - | ($3.62) | ($3.91) | ($5.40) | - | ($5.80) | ($5.60) | ($6.40) | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $152.32M | $8.67M | $10.56M | $12.56M | $9.88M | $9.99M | $19.13M | $11.89M | $10.96M | $13.01M |
| Accounts Receivable | - | - | - | - | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | $3.42M | $689.0K | $306.0K | $351.0K | $361.0K | $244.0K | - | - | - | $573.0K |
| Current Assets | $204.23M | $21.51M | $25.79M | $29.57M | $35.68M | $41.93M | $48.10M | $53.94M | $60.23M | $67.25M |
| Total Assets | $205.38M | $22.90M | $27.59M | $31.78M | $38.27M | $45.36M | $53.25M | $59.80M | $66.69M | $74.37M |
| Current Liabilities | $14.19M | $4.25M | $4.44M | $3.87M | $5.23M | $5.45M | $5.44M | $4.95M | $4.99M | $5.64M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $14.19M | $4.31M | $4.58M | $4.47M | $6.29M | $6.97M | $7.47M | $7.61M | $8.22M | $9.48M |
| Stockholders' Equity | ($137.29M) | $18.59M | $23.01M | $27.31M | $31.99M | $38.39M | $45.78M | $52.19M | $58.47M | $64.89M |
| Retained Earnings | ($453.37M) | ($283.14M) | ($278.42M) | ($273.85M) | ($268.92M) | ($262.05M) | ($254.28M) | ($247.03M) | ($239.89M) | ($231.90M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($10.73M) | - | - | - | ($7.09M) | - | - | - | ($7.62M) | - |
| Investing Cash Flow | ($31.44M) | - | - | - | $7.19M | - | - | - | $5.77M | - |
| Financing Cash Flow | $185.83M | - | - | - | ($214.0K) | - | - | - | ($209.0K) | - |
| CapEx | $6.0K | - | - | - | $0 | - | - | - | $37.0K | - |
| Free Cash Flow | ($10.74M) | - | - | - | ($7.09M) | - | - | - | ($7.65M) | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | - | - |
| FCF / Net income | 0.06 | - | - | - | 1.03 | - | - | - | 0.96 | - |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -82.9% | - | -16.6% | -15.5% | -17.9% | - | -13.6% | -11.9% | -12.0% | - |
| Return on equity | 124.0% | - | -19.9% | -18.1% | -21.5% | - | -15.8% | -13.7% | -13.7% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 14.39 | 5.06 | 5.81 | 7.64 | 6.82 | 7.70 | 8.84 | 10.90 | 12.07 | 11.92 |
| Quick ratio | 14.39 | 5.06 | 5.81 | 7.64 | 6.82 | 7.70 | 8.84 | 10.90 | 12.07 | 11.92 |
| Cash ratio | 10.73 | 2.04 | 2.38 | 3.24 | 1.89 | 1.83 | 3.52 | 2.40 | 2.19 | 2.31 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | -808.5x | -520.6x | -559.5x | - | -372.5x | -324.5x | -311.8x | - |
| Equity multiplier | -1.50 | 1.23 | 1.20 | 1.16 | 1.20 | 1.18 | 1.16 | 1.15 | 1.14 | 1.15 |
| Liabilities / Assets | 0.07 | 0.19 | 0.17 | 0.14 | 0.16 | 0.15 | 0.14 | 0.13 | 0.12 | 0.13 |
| Efficiency | ||||||||||
| Asset turnover | - | - | - | - | - | - | - | - | - | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | 0.5x | 0.4x | 6.2x | - | 6.6x | 6.0x | 9.0x | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | -2245.7% | - | 38.0% | 33.1% | 16.7% | - | -1.1% | 23.5% | 20.7% | - |
| Net income growth (YoY) | -2380.1% | - | 37.0% | 30.9% | 14.1% | - | -1.8% | 23.9% | 21.5% | - |
| EPS growth (YoY) | -2334.3% | - | 37.6% | 30.2% | 15.6% | - | -1971.4% | -1706.5% | -1839.4% | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | -51.4% | - | - | - | 7.3% | - | - | - | 35.6% | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | - | -51.6% | -49.7% | -47.7% | -45.3% | -40.8% | -35.5% | -34.1% | -38.4% | -37.2% |
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing Sensei Biotherapeutics against the 5 most active filers in the same SIC group.